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ABSTRACT 43	
 44	
Long synthetic peptides and CpG-containing oligodeoxynucleotides are promising 45	
components for cancer vaccines. In this phase I trial, 19 patients received a mean of 8 (range 46	
1-12) monthly vaccines s.c. composed of the long synthetic NY-ESO79-108 peptide and CpG-B 47	
(PF-3512676), emulsified in Montanide ISA-51. In 18/18 evaluable patients, vaccination 48	
induced antigen-specific CD8 and CD4 T-cell and antibody responses, starting early after 49	
initiation of immunotherapy and lasting at least one year. The T-cells responded antigen-50	
specifically, with strong secretion of IFNγ and TNFα, irrespective of patients’ HLAs. The 51	
most immunogenic regions of the vaccine peptide were NY-ESO-189-102 for CD8 and NY-52	
ESO-183-99 for CD4 T-cells. We discovered a novel and highly immunogenic epitope (HLA-53	
DR7/NY-ESO-187-99); 7/7 HLA-DR7+ patients generated strong CD4 T-cell responses, as 54	
detected directly ex vivo with fluorescent multimers. Thus, vaccination with the long synthetic 55	
NY-ESO-179-108 peptide combined with the strong immune adjuvant CpG-B induced 56	
integrated, robust and functional CD8 and CD4 T-cell responses in melanoma patients, 57	
supporting the further development of this immunotherapeutic approach.  58	
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INTRODUCTION 59	
Over the past years, several vaccines consisting of exactly fitting MHC class-I binding 60	
peptides have been evaluated for therapeutic efficacy in different cancer types1. Although 61	
induction of specific CD8 T-cell responses was observed2-4, absence of concomitant CD4 T-62	
cell activation may have been a reason that clinical benefit remained minimal. In agreement 63	
with this notion, inclusion of MHC class II peptides in the vaccine formulation showed 64	
superior CD8 T-cell responses in both preclinical models and clinical trials5. More recently, 65	
the use of long synthetic peptides (LSPs) harboring both CTL and T helper epitopes has 66	
demonstrated induction of strong immune responses6, 7. The additional advantages of LSPs 67	
are that they need professional APCs for efficient MHC I epitope presentation, and that their 68	
use is not limited to patients with defined HLA molecules8. In various Phase I/II clinical trials 69	
using LSPs, we and others showed potent CD8 and CD4 T-cell responses in patients with 70	
different solid cancers, as well as in pre-malignant lesions as vulvar intraepithelial neoplasia9-71	
14. 72	
 73	
The cancer germ line antigen New York esophageal squamous cell carcinoma-1 (NY-ESO-1) 74	
was discovered in 199715, and the NY-ESO-1 protein is aberrantly overexpressed in 75	
malignant transformed cells of different histological types15. During the past years, it has 76	
emerged as a potential target for cancer immunotherapy since it is highly immunogenic and 77	
includes both humoral and T-cell epitopes16. Interestingly, among all currently known NY-78	
ESO-1 T-cell epitopes, approximately half of them are present within the region 80-11117-20, 79	
making it an attractive protein stretch to be used for patient’s immunization using LSPs. 80	
 81	
Synthetic oligodeoxynucleotides (ODNs) containing unmethylated CpG (CpG–ODNs) are 82	
TLR-9 agonists. Class B CpG-ODNs directly induce activation and maturation of 83	
		 5	
plasmacytoid dendritic cells and promote B cells differentiation21. Various results in mice 84	
demonstrated the improvement of therapeutic responses of DC-based vaccines, short and long 85	
peptide immunizations and protein vaccines with this adjuvant22. Similarly, short peptide-86	
based clinical trials that included CpG-B in melanoma patients showed the generation of a 87	
stronger and more rapid Melan-A-specific CD8 T-cell response compared to the vaccine 88	
alone3. In another vaccination trial with recombinant NY-ESO-1 protein supplemented with 89	
CpG-B and Montanide, results showed a significant augmentation of tumor-specific 90	
antibodies as well as the detection of NY-ESO-1-specific CD8 T-cells23. 91	
 92	
To date, no clinical trial evaluated vaccination with CpG-B in combination with LSPs. Some 93	
recent studies assessed the safety and in vivo immunogenicity of synthetic overlapping long 94	
NY-ESO-1 peptides in combination with diverse adjuvants. In an initial study, 91% of 95	
patients in the cohort receiving the vaccine supplemented with the TLR-3 agonist Poly-ICLC 96	
showed T-cell responses, as compared to the modest specific T-cell induction in the absence 97	
of Poly-ICLC. The cellular response correlated in these patients with an acceleration of 98	
seroconversion and a significant increase in specific antibody titers14. Similar results were 99	
obtained by Tsuji et al., who characterized NY-ESO-1–specific vaccine-induced CD4 T-cell 100	
lines to investigate the effect of both Montanide and Poly-ICLC adjuvants24. While 101	
Montanide promoted a Th2 polarization and an expansion of high avidity vaccine induced 102	
CD4 T-cells through a better protein recognition, the addition of Poly-ICLC abrogated IL-4, 103	
IL-13, and IL-10 secretion, resulting in a more prominent Th1 polarization. As comparison, 104	
only half of the patients had CD8 T-cell responses when vaccinated with full NY-ESO-1 105	
protein supplemented with Montanide and CpG-B (CpG-7909/ PF-3512676)23. 106	
 107	
In this study we evaluated safety and immunogenicity of the combination of the 30 amino 108	
		 6	
acid LSP NY-ESO-179-108, administered in combination with CpG-B (CpG-7909/ PF-109	
3512676) and Montanide ISA-51 subcutaneously, accompanied or not by low dose 110	
interleukin-2, in patients with advanced malignant melanoma.   111	
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RESULTS 112	
 113	
Patients’ characteristics 114	
 115	
In this clinical trial, 19 patients with resected cutaneous melanoma of stage III or IV were 116	
enrolled in 2 groups, as summarized in Table I and supplemental Tables I-II [1.1; number 117	
labeling based on the MIATA checklist is highlighted in green throughout the manuscript]. 118	
Ten patients were in group A (without IL-2) and 9 patients in group B (with IL-2). Six (60%) 119	
and 7 (78%) patients from groups A and B, respectively, discontinued the study treatment 120	
prior to completion of the 3 vaccination cycles (Table I and Supplemental Tables I-II), mainly 121	
due to disease progression. Patient LAU 1408 received only 1 vaccine and was thus not 122	
evaluable for immune response. 123	
 124	
Expression of Melan-A, and NY-ESO-1/LAGE-1, and MAGE-A/MAGE-A10 was assessed 125	
for each patient. Table I shows TAA expression as assessed either by immunohistochemical 126	
analysis or qPCR depending on material availability [1.1]. For IHC detection of MAGE-A 127	
expression, we used clone 6C1 specific for MAGE-A1/A2/A3/A4/A6/A10 and A1225. 128	
Unfortunately, there is no MAGE-A10 mono-specific antibody available. 129	
 130	
Safety and tolerability 131	
 132	
The vaccine was generally well tolerated. Amongst all patients enrolled in groups A and B 133	
there were a total of 2 events of Grade 3 (10%) for those who were definitely, probably and 134	
possibly related to the study treatment, while no Grade 4 (life-threatening) or Grade 5 (death) 135	
adverse events were observed during the study (Supplemental Table III). 136	
		 8	
 137	
The most commonly reported adverse events were general disorders and conditions of mild 138	
intensity mainly represented by injection site reactions (rash/erythema, skin induration, pain 139	
and warmth) and systemic reactions (chills, myalgia, arthralgia, asthenia and headache). 140	
There were no severe adverse events related to the study drugs. 141	
 142	
As expected, the low dose IL-2 treatment (group B) induced frequent side effects, with 143	
inflammatory reactions at s.c. injection sites, and systemic effects (chills, fever, asthenia, 144	
headache, arthralgia, myalgia, nausea, diarrhea and insomnia). Many patients required IL-2 145	
dose reductions and/or stopped IL-2 treatment prematurely. Instead of the 45 intended 146	
injections for each patient on average, patients received 33 injections on average, resulting in 147	
an average of 73.8% of the intended cumulated dose (Supplemental Table IV). 148	
 149	
Monitoring of NY-ESO-1-specific CD8 T-cell responses 150	
 151	
A total of 18 patients were analyzed for immune responses by intracellular cytokine staining, 152	
separately for CD8 and CD4 T-cells. As shown in representative flow cytometry examples in 153	
Figures 2A and 3A, significant responses were observed both in CD8 and CD4 T-cells. 154	
Baseline frequencies of NY-ESO-1-specific CD8 T-cells were undetectable or very low in the 155	
majority of the patients (Figure 2B-C, Supplemental Figure 2A-B). However, 6 patients 156	
showed significant NY-ESO-1-specific natural responses, reaching frequencies of IFNγ and 157	
TNFα positive cells of 1.23 % of total CD8 T-cells before vaccination (Figure 2B-D and 158	
Figure 4). All patients mounted significant responses upon vaccination, as shown by the 159	
patient’s individual longitudinal curves (Figure 2B, summary in Figures 2C-D and 4). 160	
Frequencies of cytokine+ CD8 T-cells readily increased after 2-4 immunizations in the 161	
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majority of the patients. Total cytokine+ cells reached high levels, accounting for one third of 162	
total CD8 T-cells (total cytokine+ CD8 T-cells ranging from 0.05 to 33.1%). Some patients 163	
displayed a more delayed kinetics and showed initial responses only during cycle 2. Specific 164	
CD8 T-cell responses were sustained, as assessed by cytokine measurement during the third 165	
cycle of immunization (Figure 2D, Supplemental Figure 2C). No significant differences in 166	
CD8 T-cell responses were observed when Group A and Group B patients were compared. 167	
 168	
Monitoring of NY-ESO-1-specific CD4 T-cell responses and specific antibody responses 169	
 170	
Similar to CD8 T-cell responses (Figure 2), 4 out of 18 patients already showed baseline 171	
detectable frequencies of IVS specific CD4 T-cells (ranging from 0.1 - 5.77%). Nevertheless, 172	
in all patients NY-ESO-1-specific CD4 T-cells were highly significantly increased by 173	
immunization (Figure 3B-D, Supplemental Figure 3A-B). Responses were observed as early 174	
as after 2 vaccinations, and reached 70% of specific cells after IVS. They were long-lasting, 175	
since high frequencies of cytokine+ cells were detectable one year after the initiation of the 176	
trial (Figure 3D, Supplemental Figure 3C). In general, CD4 T-cell expansions occurred earlier 177	
than the ones of CD8 T-cells, suggesting that CD4 T-cell help might be necessary for specific 178	
CD8 T-cell induction (Figure 4). Responses with higher magnitude were detected at earlier 179	
time points in Group B, however long-term no difference was observed between the two 180	
groups. Importantly, not only Type I, but also Type II cytokines were detectable, arguing for 181	
the capacity of the vaccine to also impact on T-cell polarization. Type II cytokines might also 182	
have contributed to the generation of specific antibodies. We measured a significant increase 183	
in NY-ESO-1-specific antibodies in the majority of the patients, with also a discrete increase 184	
of antibodies specific for other tumor antigens, in particular Melan-A, arguing for induction 185	
of antigen spreading (Figure 4 and Supplemental Figure 4). 186	
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 187	
Determination of immunodominant regions for CD8 and CD4 T-cells, and identification 188	
of a novel HLA-DR7 specific epitope 189	
 190	
Results using individual overlapping peptides showed that the a.a. regions 90-102 and 87-99 191	
were the most immunogenic sequences for CD8 and CD4 T-cells, respectively (Figure 5A). 192	
However, the analysis of fine specificity of recognition using the set of overlapping 193	
nonapeptides revealed individual patterns (Supplemental Figure 5A), and suggests that each 194	
patient focuses CD8 T-cell responses on distinct portions of the LSP. EC50 of peptide 195	
recognition for specific CD8 T-cells ranged from micro- to nanomolar concentrations 196	
(Supplemental Figure 5B). Using HLA-B35 multimers loaded with NY-ESO-194-104, we 197	
identified specific CD8 T-cells in HLA-B35 patients not only after IVS, but also directly ex 198	
vivo (Figure 5B). For CD4 T-cells, the contribution of individual MHC class II was evaluated 199	
using blocking antibodies and HLA class II typing (Supplemental Table I). In 8/9 patients that 200	
could be included in these analyses, we observed a partial or complete abrogation of NY-201	
ESO-1-specific CD4 T-cell responses in the presence of pan-HLA-DR blocking antibodies 202	
(Figure 5C). In in vitro peptide competition assays, we identified the peptide NY-ESO-187-99 203	
as a strong binder to HLA-DR7 (data not shown). We generated DR7/NY-ESO-187-99 204	
multimers and stained IVS cultures from the 7 HLA-DR7+ patients included in our study. We 205	
identified specific cells in 7/7 HLA-DR7+ patients. As shown in a representative example in 206	
Figure 5D and as summarized in Table II multimer+ cells accounted for a large proportion of 207	
the overall response induced by vaccination. Interestingly, in all 7 HLA-DR7+ patients, 208	
multimer+ cells could be detected in samples collected before immunization. Their frequency 209	
significantly increased during time and was maintained until completion of the trial. Notably, 210	
in one patient that was previously recruited in another vaccination trial consisting of MAGE-211	
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A1 immunizations, high baseline DR7/NY-ESO-187-99 multimer+ cells were observed (e.g. 212	
19.6%). This data suggest that natural CD4 T-cell responses to the novel NY-ESO-1 epitope 213	
might have been induced in this patient by antigen spreading upon vaccination with MAGE-214	
A1 peptide. 215	
 216	
Polyfunctionality and cytolytic activity of HLA-DR7/NY-ESO-187-99-specific CD4 T-cell 217	
clones 218	
 219	
We generated HLA-DR7/NY-ESO-187-99-specific CD4 T-cell clones and lines from 4 HLA-220	
DR7+ patients (Figure 6A, upper panel). By functional characterization we defined the peptide 221	
87-99 as the minimal epitope inducing maximal responses in 15/19 of the clones (data not 222	
shown). Clones responded by secreting both Th1 and Th2-prototypic cytokines, albeit with a 223	
different EC50 (Figure 6A, lower panel). Then, we assessed whether DR7/NY-ESO-187-99-224	
specific cells are able to recognize the newly identified NY-ESO-1 epitope when presented by 225	
tumor cells. We used HLA-DR7+/- melanoma cell lines, pre-treated or not with IFNγ, and co-226	
cultured them with specific CD4 T-cell clones. We observed that specific clones secreted 227	
significant amounts of cytokines in response to NY-ESO-1/DR7 peptide presented by tumor 228	
cells (Figure 6B, left panel). We also assessed whether NY-ESO-187-99 CD4 T-cell clones 229	
could directly kill target cells. When co-cultured with 3 different HLA-DR7+ melanoma cell 230	
lines, displaying either endogenous or IFNγ-induced MHC II expression, the clones induced 231	
significant tumor cell lysis of the HLA-DR7+ tumor cells, pulsed with the specific peptide 232	
(Figure 6B, right panel). As expected, HLA-DR7- tumor cells were not susceptible to killing. 233	
 234	
Direct ex vivo visualization of HLA-DR7/NY-ESO-187-99-specific CD4 T-cells 235	
 236	
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Finally, we performed multicolor flow cytometry analyses directly ex vivo (without prior in 237	
vitro T-cell expansion) from HLA-DR7+ patients. Remarkably, in 7/7 patients we were able to 238	
detect multimer+ cells without prior in vitro stimulation (representative examples in Figure 6C, 239	
summary in Figure 6D). Their frequencies varied between 0.01 and 0.18% of total CD4 T-240	
cells, and their phenotype corresponded to antigen-experienced, memory cells (data not 241	
shown). 242	
 243	
Follow-up and clinical observations 244	
 245	
The median follow up time was 63.8 months for group A (ranging from 8.5 to 80.5 months) 246	
and 55.9 months for group B (ranging from 2.2 to 68.4 months) at the time of analysis 247	
(December 8th, 2015). Overall, the median follow up time was 56.8 months (with a range 248	
from 2.2 to 80.5 months). At the last follow-up, twelve patients were alive (5 of group A and 249	
7 of group B), whereas 7 patients died (5 of group A and 2 of group B) due to progressive 250	
disease. Eight patients (4 patients of each of the two groups) remained without evidence of 251	
disease (Table I). Patients with above median levels of IFNγ+ NY-ESO-1-specific CD4 T-252	
cells showed tendencies for longer overall and progression-free survival than patients with 253	
below median levels, but the differences were not statistically significant (Figure 7). These 254	
clinical results are relatively favorable, but not conclusive as expected for a phase I study.   255	
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DISCUSSION 256	
 257	
Montanide in combination with TLR3 agonists and LSPs has been shown to elicit both 258	
humoral and cellular responses in cancer patients14, 24. Here, we assessed for the first time the 259	
combination of Montanide, CpG-B and LSP in advanced melanoma patients. We report on 260	
the induction of strong and long-lasting polyspecific CD8 and CD4 T-cell responses, with T-261	
cells able to recognize and kill tumor cells, and the generation of specific antibodies. By in-262	
depth characterization of the induced CD4 T-cell responses, we identified a novel, 263	
immunodominant HLA-DR7 restricted NY-ESO-1 epitope, that triggers CD4 T-cells 264	
detectable directly ex vivo in all evaluable patients. Hence, combination of LSP and CpG-B 265	
represents an attractive immunotherapy strategy in cancer patients, beyond virus-driven 266	
tumors. 267	
 268	
DNA containing CG repeats, mimicked by CpG-ODN, ligate TLR9 and induce production of 269	
TNFα (CpG-B) or IFNα (CpG-A). Thus, CpG-ODN are considered the most advanced danger 270	
signals for the development of adjuvants for immunotherapy. CpG-A ODNs spontaneously 271	
assembly in nanoparticles26 and have been shown to induce tumor specific CD8 T-cell 272	
responses in VLP based vaccines27. Yet, current evidence suggests that CpG-B might be 273	
superior, as previously reported by us and others in adjuvanted short peptide- and protein-274	
based trials2, 3, 23, 28-30. 275	
Here, we show that the combination of CpG-B and a 30-amino acid long peptide is safe and 276	
well tolerated by the majority of the patients. Short peptide-based vaccines have the 277	
disadvantage to be limited for use in selected cohorts of HLA-compatible patients, and harbor 278	
the potential hazard to directly bind to MHC molecules and induce tolerance31. In contrast, 279	
full protein-based vaccines depend on processing for epitope generation, lead to a broad 280	
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spectrum of T-cell epitopes and induce antibody responses; however, they are expensive, 281	
might lead to the generation of poorly immunogenic epitopes, and are often suboptimal in 282	
inducing CD8 T-cell responses32. Therefore, selection of strong and immunogenic LSP has 283	
proven interesting. Hence, patients with HPV-driven pre-malignant and malignant tumors 284	
treated with E6/E7 LSP show immunological10, 11, 33, preclinical and clinical benefits12, 34, and 285	
combination of a TLR3 agonist with overlapping LSP from NY-ESO-1 also resulted in 286	
significant T-cell induction in ovarian cancer patients14, 24. Here, we observe early onset, 287	
highly significant, sustained NY-ESO-1-specific CD4 T-cell responses, followed by very high 288	
frequencies of specific CD8 T-cells, in all patients. Importantly, kinetics of CD8 T-cell 289	
responses are delayed compared to CD4 T-cells, suggesting that helper CD4 T-cells35 and 290	
CpG induced DC-activation might play a critical role in activating and sustaining the effector 291	
phase of CD8 T-cells. Moreover, by deconvoluting the specific T-cell responses using 292	
individual overlapping peptides, we show that CD8 T-cells recognize different regions of the 293	
LSP, while CD4 T-cell responses are confined to a common stretch of the LSP (aa 83-97). 294	
These data suggest that in contrast to short peptide and protein vaccination, the use of a LSP 295	
allows generation of multiple MHC class I epitopes36, likely favored by the presence of CpG. 296	
Immunodominant regions for CD8 T-cells in the LSP sequence are heterogeneous and 297	
probably linked to the MHC class I of the patients. HLA-B35+ patients showed directly ex 298	
vivo detectable CD8 T-cell responses to a known NY-ESO-1-B35 epitope, while HLA-B35- 299	
patients mounted responses to other regions of the LSP, including putative novel MHC class I 300	
epitopes. In contrast, different MHC class II molecules might efficiently bind peptides 301	
processed from the region 83-97 and promiscuously present the same peptide, as previously 302	
shown by us and others for other epitopes from tumor-associated antigens17, 37. In that regard, 303	
numerous publications have reported on the immunogenicity of NY-ESO-1, and in particular 304	
of the protein region 87-11117, 18, 20, 38. Mandic et al. previously reported on the 305	
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characterization of a CD4 T-cell clone recognizing the epitope 87-101 presented by HLA-306	
DR7 transfected cells17, By fine mapping of specific CD4 T-cell responses in our cohort of 307	
HLA-DR7+ patients, we identified NY-ESO-1 87-99 as a minimal, immunogenic epitope 308	
presented by HLA-DR7. Importantly, the presence of directly ex vivo detectable DR7-309	
restricted NY-ESO-1-specific CD4 T-cells in patients even before immunization convincingly 310	
show the endogenous generation of this epitope. Given the abundance of this HLA in the 311	
Caucasian population (25%) further evaluation of directly ex vivo and in vitro expanded 312	
DR7/NY-ESO-1-specific CD4 T-cells is warranted. By comparing frequencies of total 313	
cytokine+ CD4 T-cells to those of multimer+ CD4 T-cells after IVS, our initial quantification 314	
points towards a dominant contribution of the DR7-restricted response to the total specific T-315	
cell response. Furthermore, phenotypic and functional characterization of DR7/NY-ESO-1 T-316	
cells indicates a predominant Th1 polarization. Yet, by stimulating specific clones with high 317	
peptide doses we observed secretion of Type-2 cytokines, arguing for plasticity and 318	
polyfunctionality of these cells. In that regard, it was previously reported both in mice and 319	
primates that TLR9 agonists induce potent antitumor effects, through induction of adaptive 320	
Th1 cellular responses. Inversely, Montanide seems to favor Th2 differentiation of vaccine-321	
induced TAA-specific CD4 T-cells39, suggesting that a careful evaluation of adjuvant and 322	
peptide doses are needed to optimize vaccinations based on LSP with CpG-B/Montanide 323	
combination, as compared to other adjuvants. In addition, caution will be needed when LSP 324	
and potent molecularly-defined immune adjuvants are used, in order to avoid life threatening 325	
immune responses and vaccine toxicity, as reported in a murine study using HY-LSP 326	
combined with CpG40. Nevertheless, an advantage in the utilization of TLR9 agonists, but not 327	
TLR4, TLR5 or TLR7-agonists41, is the ability of CpG to safely tilt the immunologic balance 328	
towards effector rather than regulatory T-cells 29, 42, thus favoring the overcoming of immune 329	
tolerance. The direct ex vivo phenotypic characterization of DR7/NY-ESO-1 CD4 T-cells 330	
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showed very low levels of regulatory T-cells upon immunization (data not shown), in line 331	
with our previous results29. 332	
Finally, beside Type 1 cytokine secretion upon co-culture with HLA-matched tumor cells, 333	
DR7/NY-ESO-1 CD4 T-cells were also able to directly kill targets. Importantly, beside 334	
implications of killer specific CD4 T-cells against viruses, recent reports on killer CD4 T-335	
cells in solid tumors have emerged43. It was recently reported on the potent rejection of 336	
melanoma in lymphopenic mice after transfer of small numbers of naive CD4 T-cells in 337	
combination with CTLA-4 blockade44. Similarly, co-culture of antigen-specific CD4 T-cells 338	
obtained from patients treated with anti-CTLA-4 antibodies specifically recognized and killed 339	
tumors45. In parallel, an increased killing capacity of specific CD4 T-cells was triggered via 340	
OX40/OX40L in combination with chemotherapy46. Additional work is needed to define the 341	
exact contribution of these cells to tumor eradication and the potential involvement of CpG-B 342	
in their generation. Moreover, it will be of interest to determine antigen recognition of 343	
endogenously processed antigens by tumor cells as compared to professional APCs. In this 344	
context, it has recently been shown that in addition to endosomal/lysosomal proteases that are 345	
typically involved in MHC class II antigen processing, other pathways usually used for MHC 346	
class I presentation, could also be involved in the presentation of intracellular NY-ESO-1 on 347	
MHC class II by ovarian tumor cells47. Thus, these observations suggest that inclusion of 348	
multiple LSP from different TAA in optimized vaccine formulations might exploit these 349	
novel pathways, favor the induction of epitope spreading and promote the generation of 350	
robust and combined CD8 and CD4 T-cell, and humoral responses. 351	
We did not observe significant differences in the results from patients without vs. with IL-2 352	
treatment, even though a trend for stronger CD4 T-cell responses was observed in the patients 353	
receiving IL-2, at the early immunomonitoring time points. This contradicts previous studies 354	
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showing that frequencies of tumor-antigen specific T-cells are reduced in the blood of patients 355	
treated with low dose IL-2, likely due to T-cell emigration into peripheral tissues48, 49. 356	
However, the IL-2 doses delivered in our study were very low, and therefore perhaps without 357	
significant consequences for T-cell functions. Despite the very low doses, patients 358	
experienced many adverse events typical for IL-2 treatment. The maximally tolerated dose 359	
was as low as 1 Mio UI/m2/day, thus significantly lower than what is conventionally regarded 360	
as low dose IL-2 therapy. We suspect that the concomitant treatment with CpG-B may have 361	
contributed to this relatively high toxicity, because previous peptide/Montanide vaccination 362	
studies without CpG showed lower toxicity despite higher IL-2 doses50. However, a direct 363	
comparison is required to determine a potential role of CpG-B in IL-2 toxicity. 364	
Finally, we observed a trend for longer overall and progression-free survival in patients with 365	
above median levels of IFNγ+ NY-ESO-1-specific CD4 T-cells. However, beside the 8 366	
patients that remained without evidence of disease throughout the study, the others 367	
experienced progressive disease. The discrepancy between strong immunological and only 368	
modest clinical responses might be due to the fact our trial was performed in advanced 369	
melanoma patients (stage III/IV). In addition, we monitored T-cell responses in the circulation, 370	
but not at tumor site. We and others previously showed that local tumor-derived factors might 371	
block efficient immune responses in tumors2. Future studies on tumor-infiltrating 372	
lymphocytes in patients receiving LSP combined with CpG will provide additional 373	
information on T-cell fitness directly at tumor site. 374	
In conclusion, the high immunogenicity power of NY-ESO-179-108 LSP combined with CpG-375	
B, the relatively low synthesis costs and the relative ease of production defines this vaccine 376	
formulation as a great candidate to be explored for cancer immunotherapy.  377	
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MATERIALS AND METHODS 378	
 379	
Study Design, Patients and Treatment 380	
 381	
This is a phase I vaccination study of stage III and IV (American Joint Committee on Cancer-382	
AJCC) malignant melanoma patients [1.1]. The vaccines were composed of clinical-grade 383	
antigenic peptides, CpG-B 7909/PF-3512676 (Pfizer Inc) and Montanide ISA-51 (Seppic SA) 384	
and were administered subcutaneously (s.c.). Antigenic peptides were the 30-amino acid long 385	
NY-ESO-179-108 peptide (for all patients), and the short HLA-A2 restricted peptides Melan-386	
A26-35 (native EAAGIGILTV), Melan-A26-35(A27L) (analog ELAGIGILTV) and MAGE-A10254-387	
262 (GLYDGMEHL) (only for HLA-A2 positive patients). Vaccinations were administered in 388	
cycles of 4 monthly vaccines with intervals of 2 months between the cycles (Figure 1). 389	
 390	
The primary objectives of the study were safety and specific cellular immune responses to 391	
NY-ESO-1, Melan-A and MAGE-A10. The secondary endpoints were tumor responses and 392	
disease status. Nineteen patients were enrolled in this study and first assigned to group A 393	
(without IL-2), followed by group B with supplementary daily low dose IL-2 (Novartis) s.c. 394	
for 10 days after each vaccination, starting the day of the second vaccination up to the end of 395	
cycle 3. IL-2 was administered following a dose escalation scheme (3 doses injected: 0.5, 1 or 396	
2 Mio UI/m2/day). For inclusion, tumors had to express either NY-ESO-1 (LAGE-2) or 397	
LAGE-1, and Melan-A in HLA-A2 positive patients (HLA haplotype analysis and 398	
immunohistochemistry/PCR for TAA expression was performed on tumor biopsies, after 399	
given written informed consent [1.1]). 400	
. 401	
 402	
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Administered vaccines were composed of 0.5 mg NY-ESO-179-108 peptide, 1 mg CpG-B 403	
7909/PF-3512676 and 0.5 ml Montanide (syringe 1). HLA-A2+ patients received a second 404	
injection (syringe 2), with the short Melan-A26-35 and MAGE-A10254-262 peptides, 1 mg CpG-405	
B and 0.5 ml Montanide. The three vaccines of the cycle 3 were formulated without 406	
Montanide. The short peptides were given in a “prime-boost” approach, as follows: for the 407	
first cycle 0.1 mg Melan-A26-35 natural peptide and 0.02 mg MAGE-A10254-262 peptide, and 408	
for the following cycles 0.1 mg Melan-A26-35(A27L) analog peptide and 0.1 mg MAGE-A10254-409	
262 peptide. A total of 19 immunocompetent patients (5 female and 14 male) with median age 410	
of 59 years old were vaccinated [1.1]. 411	
 412	
Disease status was assessed every 3 months for patients with measurable disease and every 6 413	
months for patients with no measurable disease. The study (NCT00112242) sponsored by the 414	
Ludwig Center for Cancer Research was approved by the Lausanne University Hospital 415	
Ethics Committee and written informed consent was obtained from patients prior to enrolment. 416	
Safety was evaluated according to the National Cancer Institute CTC Scale (Version 2.0; 417	
April 30, 1999). 418	
This study was performed under GLP conditions [5.1], following SOP developed in the 419	
laboratory [5.4] and using investigative assays [5.5]. 420	
 421	
Blood collection and PBMCs isolation 422	
 423	
Heparinized blood samples were withdrawn by venipuncture [1.2, 1.3, 1.4] at baseline, after 2 424	
and 4 vaccinations during the first cycle and at the end of each of the following cycles. 425	
Peripheral blood mononuclear cells were isolated by Lymphoprep centrifugation gradient 426	
[1.6] from blood kept at room temperature [1.5] no longer than 4 hours following blood 427	
drawn [1.7]. Isolated PBMCs were immediately stored in cryovials at 10 x 106 cells in 1ml of 428	
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cold 50% RPMI (Gibco), 40% FCS (PAA laboratories) and 10% DMSO freezing medium 429	
(Sigma Aldrich) [1.9, 1.12] at -80°C, and further into liquid nitrogen until use [1.10, 1.11]. 430	
Before freezing cells were counted using trypan blue [1.20] and viability was >95% [1.15, 431	
1.16]. 432	
Cryopreserved cells were thawed at 37°C, washed once and resuspended at the desired 433	
concentration in RPMI supplemented with 10% FCS, 1.15% nonessential amino acids 434	
(Sigma), 1% penicillin streptomycin (Sigma), 1% Hepes buffer (Gibco, Life Tchnologies) 435	
[2.3]. Cells were resuspended in RPMI (Gibco), 8% Human Serum (pooled human sera from 436	
healthy donors’ blood from the local blood bank), 1% nonessential amino acids, 1% 437	
penicillin-streptomycin, 1% L. glutamine (Gibco, Life Technologies), 1% sodium pyruvate 438	
(Gibco, Life Technologies), and 0.1% 2-mercaptoethanol (Sigma) [2.1] and counted using 439	
trypan blue [1.20] with viability >80% [1.15, 1.17]. 440	
Cell media supplemented with serum were negative from previous tests for extracellular 441	
contamination sources [2.2]. 442	
 443	
Peptide/MHC Multimers 444	
 445	
Fluorescent mulitmers were: HLA-B35/NY-ESO-194-104, HLA-DR*0701/NY-ESO-187-99. All 446	
multimers were provided by TCMetrix [2.4]. 447	
 448	
In vitro peptide stimulation (IVS) of CD8 and CD4 T-cells 449	
 450	
Patients’ CD8 T-cells were purified by positive selection using MACS isolation microbeads 451	
(Miltenyi), followed by CD4 T-cell positive selection starting from the CD8 negative fraction. 452	
Positive T-cells were stimulated in vitro (IVS) and CD4/CD8 depleted PBMCs were 453	
irradiated (30 Gy) and used as feeders for stimulation of the cultures [2.4]. T-cells and 454	
autologous APCs were mixed at 1:1 ratio and co-cultured for 14 days with three 18-mers 455	
(NY-ESO-179-96, NY-ESO-185-102, NY-ESO-191-108) spanning the entire vaccine NY-ESO-179-456	
108 sequence, with 12 amino acids overlaps, at 2 µM, in RPMI 1640 medium supplemented 457	
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with 8% heat inactivated, pooled human serum. In parallel, a CD4 T-cell blast culture was set 458	
up using 1 µg/ml PHA. At day 2, 100 U/ml IL-2 was added and cultured until day 14 [2.1, 459	
2.4]. 460	
NY-ESO-179-108-specific T-cell responses were evaluated after IVS in a 6-hour re-challenge 461	
experiment using overlapping peptide pools (2 µM final concentration) in the presence of 462	
Brefeldin A (10 µg/ml): for evaluation of CD4 T-cell responses 10 13-mer peptides 463	
overlapping by 11 amino acids were used, while for CD8 T-cell responses 22 9-mer peptides 464	
were pulsed on autologous PHA CD4 T-cell blasts for 1 hour, before addition to the CD8 T-465	
cells [2.4]. As negative control, cells from the same cultures were left unchallenged and as 466	
positive control, 2 wells for CD8 and CD4 T-cells were stimulated with PMA/Ionomycin in 467	
the presence of Brefeldin A (Figure 2) [2.5]. 468	
 469	
NY-ESO-1 restimulated T-cells were evaluated for IFNγ, TNFα, and IL-2 production and 470	
analyzed by flow cytometry. Additionally, CD4 T-cells were concomitantly analyzed for IL-5 471	
and IL-13 production. Cells were first stained for CD3-APC AF750 (BD Biosciences), CD4-472	
PB (BD Pharmingen) and CD8-ECD (Beckman Coulter) and Live/Dead Aqua (Invitrogen), 473	
followed by a fixation step. Cells were washed with buffer (PBS, 0.2% BSA, 0.2% azide, 5 474	
µM EDTA) and permeabilized with 0.1% saponin for staining for IL-2-FITC (BD 475	
Pharmingen), IFNγ-PECy7 (BD Pharmingen), TNFα-AF700 (BD Pharmingen) for read out of 476	
CD8, while CD4 T-cells were additionally stained for IL-5 and IL-13-APC (BD Biosciences) 477	
[2.4]. Samples were aquired on a Gallios flow cytometer (Beckman Coulter) and data were 478	
analyzed using FlowJo software (TreeStar) [3.1, 3.2]. The PMT voltages were adjusted for 479	
each fluorescence channel using unstained PBMCs and compensations were set using PBMCs 480	
stained with single antibodies according to a local SOP [3.2]. The analysis was performed on 481	
living, singlets, CD3+CD4+ or CD3+CD8+ lymphocytes [3.3]. A representative example of the 482	
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full gating strategy is shown on Supplementary Figure 6 [3.4]. Dot plots can be provided per 483	
request [4.3]. Stainings were considered as positive for each measured cytokine if the 484	
stimulated responses were at least three times higher than the unstimulated control [4.4] as 485	
defined during the study design [4.6]. 486	
 487	
Generation of HLA-DR7-restricted NY-ESO-187-99-specific CD4 T-cell clones and lines 488	
 489	
Polyclonal cultures from HLA-DR7 patients containing NY-ESO-187-99-specific CD4 T-cells 490	
were sorted using NY-ESO-187-99/HLA-DR7 multimers by fluorescence activated cell sorting 491	
following the staining panel: anti-CD4 and anti-CD3 antibodies, DAPI and PE-conjugated 492	
NY-ESO-187-99/HLA-DR7 multimer [4.6]. Clones were obtained by limiting dilution (0.5 493	
cell/well) in Terasaki plates and cultured in RPMI medium with 8% HS and 100 U/ml IL-2, 494	
10000 irradiated allogenic feeder cells per well and 1 µg/ml PHA [2.4]. Unstained cultures 495	
from the same patients were used as controls [2.5]. 496	
 497	
Direct ex vivo enumeration of HLA-DR7-restricted NY-ESO-187-99-specific CD4 T-cells 498	
 499	
PBMCs from HLA-DR7+ patients were stained directly ex vivo using a combination of PE-500	
conjugated NY-ESO-187-99/HLA-DR7 multimer, followed by staining using PerCP-Cy5.5-501	
conjugated anti-CD3 (Biolegend), AF700-conjugated anti-CD45RA (Biolegend), APC-H7 502	
conjugated anti-CD4 (BD Bioscience) and Vivid Aqua (Invitrogen). 503	
 504	
Killing Assay  505	
 506	
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The specific lytic activity of the NY-ESO-187-99 CD4 T-cell lines was assessed against HLA-507	
DR7+ (T331A; GEF I; GEF II) or HLA-DR7- (T1415A) melanoma cell lines, pre-treated or 508	
not with hrIFNγ (50 U/ml, Peprotech) for 48 hours [2.4]. Cells were labeled with 51Chromium 509	
(Amersham Biosciences), loaded or not with peptides, and washed [2.4]. Labeled target cells 510	
were incubated with effectors at the indicated ratio for 4 hours at 37°C [2.4]. The supernatants 511	
were harvested and radioactivity was counted in an automatic gamma-counter [3.1]. The 512	
percentage of specific lysis was determined using the formula: (experimental-spontaneous 513	
release)/(maximum-spontaneous) x 100. Internal controls were included in each assay to 514	
measure the spontaneous release (target cells alone) and the total release (target cells with 1 515	
M HCl) [2.5]. 516	
 517	
IFNγ ELISA 518	
 519	
NY-ESO-187-99 CD4 T-cells were co-cultured at 1:1 ratio with HLA-DR7+ (T331A; GEF I; 520	
GEF II) or HLA-DR7- (T1415A) melanoma cell lines, pre-treated or not with hrIFNγ (50 521	
U/ml, Peptrotech) for 48 hours, pulsed or not with peptides [2.4]. Supernatants from 522	
stimulated conditions and unstimulated controls [2.5] were harvested after 24 hours and IFNγ 523	
ELISA was performed using the Human BD OptEIA ELISA set (BD Biosciences) [2.4, 3.1]. 524	
 525	
IFNγ ELISPOT 526	
 527	
The Elispot was performed using the ELISpotPRO kit for Human IFN-γ from MABTECH 528	
(3420-2APT-10), following the standard supplier instructions. CD8 T-cells after IVS were 529	
thawed and rested in presence of 100 U/ml IL-2 for two days before use. The cell number per 530	
well was adjusted to have maximum 3% of cytokine producing cells per well to avoid 531	
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saturation of the membrane (values taken from the previous immune monitoring). For the 532	
analysis the values had been normalized to equal percentages of spot forming units (SFU) 533	
[2.4]. 534	
 535	
Serology 536	
 537	
Recombinant NY-ESO-1 protein and control dihydrofolate reductase (DHFR) proteins were 538	
used to coat plates and measure specific serum antibody levels in ELISA as previously 539	
described14 [2.4, 2.5]. A reciprocal titer was estimated from optical density readings of 540	
serially diluted plasma samples. Negative control sera from healthy individual and positive 541	
control sera for each antigen from patients with cancer were always included [2.5]. The anti-542	
human immunoglobulin antibodies used as secondary reagents were: alkaline phosphatase 543	
(AP)-labeled goat-anti-human IgG (polyclonal antisera; Southern Biotech), biotinylated 544	
mouse-anti-human IgG1 (Clone JDC-1; BD Pharmingen), AP-labeled mouse anti-human 545	
IgG2 (clone HP6002; Southern Biotech), AP-labeled mouse anti-human IgG3 (clone HP6050; 546	
Southern Biotech), AP-labeled mouse anti-human IgG4 (clone HP6023; Southern Biotech), 547	
AP-labeled goat-anti-human IgA (polyclonal antisera; Southern Biotech), AP-labeled mouse-548	
anti-human IgD-AP (clone IADB6; Southern Biotech), AP-labeled goat-anti-human IgE 549	
(Clone HP6029; Southern Biotech) [2.4], and AP-labeled goat-anti-human IgM (polyclonal 550	
antisera; Southern Biotech). To be considered significant, reciprocal titers had to be more than 551	
100 [4.4]. 552	
 553	
Tumor responses 554	
 555	
In patients with measurable disease, tumor responses were classified as follows: complete 556	
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response as disappearance of all the tumor signs for at least 4 weeks, partial response as 557	
decrease of at least 50% of all tumor lesions for at least 4 weeks, minor response as decrease 558	
of all the lesions by at least 25% for the same minimum period of time, stable disease as no 559	
more than 25% changes in size of previous lesions for the same minimum period of time, 560	
progressive disease as appearance of new lesions or increased lesions by at least 25% in size, 561	
and major progressive disease as tumor progression requiring other standard therapy 562	
comprising chemotherapy and /or radiotherapy [4.6]. 563	
 564	
Statistical Analyses 565	
 566	
In IVS, baseline values from the same unstimulated CD8 and CD4 T-cell cultures were used 567	
as negative control and excluded from the peptide challenged responses [2.5]. For each 568	
patient and each time point at least 6 individual cultures were analyzed [2.8]. Vaccination 569	
effects on tumor specific CD8 and CD4 T-cell responses were analyzed according to the 570	
vaccination schedule and relative to the same results at study entry. For statistical analysis 571	
unpaired Kruskal-Wallis test was used. For all analyses, a p value less than 0.05 was 572	
considered as statistically significant and labeled with *, very significant less than 0.01 with 573	
**, strongly significant less than 0.001 with *** and less than 0.0001 with **** [4.4]. Not 574	
significant differences were labeled with ns.  575	
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FIGURE LEGENDS 788	
 789	
Figure 1: Study design. Vaccinations (V) consisted of three cycles (C1-C3) of four monthly 790	
subcutaneous (s.c.) injections of 0.5 mg of NY-ESO-179-108 long peptide. HLA-A2+ patients 791	
were also vaccinated with 0.1 mg of Melan-A26-35 native peptide and 20µg of Mage-A10254-262 792	
peptide in the first cycle, followed by 0.1 mg Melan-A26-35(A27L) analog peptide and 0.1 mg of 793	
Mage-A10254-262 peptide in the following cycles. In addition, Group B patients were treated 794	
with low dose rh-IL-2. Peptides for HLA-A2+ patients were emulsified in 1 ml Montanide® 795	
ISA-51 and 2 mg CpG-7909/PF-3512676, peptides for HLA-A2- patients were emulsified in 796	
0.5 ml Montanide® ISA-51 and 1 mg CpG-7909/PF-3512676. The 3 vaccines of the cycle 3 797	
were formulated without Montanide. Blood samples were withdrawn and PBMC were 798	
prepared at baseline (100 ml), after 2 vaccinations (2 samples at 7 days interval: 30 and 100 799	
ml) and after 4 vaccinations (2 samples at 7 days interval: 30 and 100 ml) for the assessment 800	
of immune responses. 801	
 802	
Figure 2: Specific CD8 T-cell responses before and after vaccination with NY-ESO-1 803	
LSP. A. Representative example of a NY-ESO-1-specific CD8 T-cell response 14 days after 804	
IVS. Cytokine secreting cells are enumerated after 6-hour challenging of the expanded cells 805	
with the NY-ESO-1 pool of overlapping peptides, or without any peptide as control. B. 806	
Details of longitudinal NY-ESO-1-specific CD8 T-cell responses (IFNγ, TNFα, and IL-2) 807	
measured individually in each patient before and during vaccination. C. Polyfunctionality of 808	
NY-ESO-1-specific CD8 T-cell responses assessed as IFNγ+TNFα+ or IFNγ+TNFα+IL-2+ 809	
cells, measured individually in each patient before and during vaccination. D. Quantification 810	
of the contribution of each individual cytokine (IFNγ, TNFα and IL-2) to the NY-ESO-1-811	
specific CD8 T-cell response, before and during vaccination. The mean of the response for 812	
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each cytokine is shown for all patients grouped as % of the total response (that is defined as 813	
100%). The	magnitude	(mean	for	all	patients	grouped)	of	the	total	response	at	each	time	814	 point	is	indicated	on	the	bottom	of	each	pie. 815	
 816	
Figure 3: Specific CD4 T-cell responses before and after vaccination with NY-ESO-1 817	
LSP. A. Representative example of a NY-ESO-1-specific CD4 T-cell response 14 days after 818	
IVS. Cytokine secreting cells are enumerated after 6-hour challenging of the expanded cells 819	
with the NY-ESO-1 pool of overlapping peptides, or without any peptide as control. B. 820	
Details of longitudinal NY-ESO-1-specific CD4 T-cell responses (IFNγ, TNFα, IL2 and IL-821	
13) measured individually in each patient before and during vaccination. C. Polyfunctionality 822	
of NY-ESO-1-specific CD4 T-cell responses assessed as IFNγ+TNFα+, or IFNγ+TNFα+IL-2+, 823	
or IFNγ+TNFα+IL-2+IL-13+ cells, measured individually in each patient before and during 824	
vaccination. D. Quantification of the contribution of each individual cytokine (IFNγ, TNFα, 825	
IL-13 and IL-2) to the NY-ESO-1-specific CD4 T-cell responses, before and during 826	
vaccination. The mean of the response for each cytokine is shown for all patients grouped 827	
as % of the total response (that is defined as 100%). The	magnitude	(mean	for	all	patients	828	 grouped)	of	the	total	response	at	each	time	point	is	indicated	on	the	bottom	of	each	pie. 829	
 830	
Figure 4: Summary of NY-ESO-1-specific CD8 and CD4 T-cell responses, and antibody 831	
responses. Cellular responses were measured 14 days after IVS and humoral responses were 832	
analysed by ELISA against the NY-ESO-1 protein in plasma collected from enrolled patients’ 833	
pre- treatment and during treatment as indicated. 834	
 835	
Figure 5: Mapping of NY-ESO-1-specific CD8 and CD4 T-cell responses. A. Using 836	
individual overlapping peptides covering the entire NY-ESO-1 LSP sequence, NY-ESO-1-837	
		 34	
specific CD8 T-cell responses (n=5 patients) and CD4 T-cell responses (n=9 patients) were 838	
mapped, by monitoring IFNγ+TNFα (CD8 T-cells) and IFNγ (CD4 T-cells) production after 839	
6-hour peptide challenge. B. Representative example of NY-ESO-194-104/B35 multimer 840	
staining directly ex vivo and after IVS of CD8 T-cells from HLA-B35+ patients. C. MHC 841	
class II restriction of NY-ESO-1-specific CD4 T-cell responses was assessed in a 6-hour 842	
peptide challenge in the absence or presence of blocking anti-DR, -DP, or DQ antibodies. 843	
Specific responses were measured by quantification of IFNγ production. D. Representative 844	
example of NY-ESO-187-99/DR7 multimer staining of IVS CD4 T-cells obtained from HLA-845	
DR7+ patients, before and during immunization. 846	
 847	
Figure 6: NY-ESO-187-99 peptide represents a novel MHC II epitope. A. NY-ESO-187-99-848	
specific CD4 T-cell clones were generated and stained with NY-ESO-1/DR7 multimers 849	
(upper panels). Reactivity to specific peptide was tested and EC50 was calculated for both 850	
Type1 and Type2 cytokines (lower panels). B. NY-ESO-187-99-specific-CD4 T-cell clones 851	
were assessed for their capacity to secrete IFNγ or kill HLA-DR7+ targeT-cells, in the 852	
presence or absence of specific peptide. C. Representative example of direct ex vivo multimer 853	
staining of NY-ESO-187-99-specific-CD4 T-cells in HLA-DR7+ patients. D. Summary of 854	
frequencies of direct ex vivo detectable NY-ESO-187-99-specific-CD4 T-cells in HLA-DR7+ 855	
patients. 856	
 857	
Figure 7: Overall survival and progression-free survival depending on the maximal level 858	
of IFNγ+ NY-ESO-1-specific CD8 T-cell (A) and CD4 T-cell (B) frequencies reached during 859	
the study after IVS. A. Overall survival (left panel) and progression-free survival (right panel) 860	
in patients with low frequencies of IFNγ+ NY-ESO-1-specific CD8 T-cells (lower than the 861	
median, n=9) and in patients with high frequencies of IFNγ+ NY-ESO-1-specific CD8 T-cells 862	
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(higher than the median, n=9). B. Overall survival (left panel) and progression-free survival 863	
(right panel) in patients with low frequencies of IFNγ+ NY-ESO-1-specific CD4 T-cells 864	
(lower than the median, n=9) and in patients with high frequencies of IFNγ+ NY-ESO-1-865	
specific CD4 T-cells (higher than the median, n=9). 	  866	
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Table I: Patients’ characteristics 867	
868	
   869	
Study	entry Study	end Best	response
Group	A	(no	IL-2)
LAU	986 M 35 IIIA 12 NED NED NED 63.8 63.8
LAU	205 M 36 IV 2 ED PD PD 73.6 8.5 PD
LAU	331 M 45 IV 18 NED NED NED 80.5 80.5
LAU	518 M 65 IV 9 ED PD PD 5.8 33.1 PD
LAU	1280 M 59 IIIB 8 NED PD NED 9.4 11.4 PD
LAU	1330 M 61 IIIC 8 NED PD PD 3.5 11.3 PD
LAU	1293 F 65 IV 12 NED NED NED 49.9 49.9
LAU	1286 F 31 IIIC 10 NED NED NED 71.6 71.6 Patient's	choice
LAU	1352 M 65 IIIC 12 NED PD NED 14.0 24.5
LAU	1350 M 61 IV 6 ED PD PD 3.9 34.6 PD
all	patients 2/8 60	(31-65) 10	(2-18) 32.0 33.8
Group	B	(IL-2)
LAU	1357 M 58 IIIB 12	+	IL-2 NED NED* NED 6.7 68.4
LAU	1397 F 36 IIIC 8	+	IL-2 NED PD NED 8.7 61.2 PD
LAU	1408 M 64 IIIB 1 NED PD PD 1.1 2.2 Degraded	health	
status
LAU	1415 M 46 IV 5	+	IL-2 NED PD NED 5.1 12.4 PD
LAU	1417 M 67 IIIA 8	+	IL-2 NED PD NED 8.0 55.9 PD
LAU	466 F 65 IV 2	+	IL-2 NED NED NED 41.3 41.3 Patient's	choice	
LAU	1394 M 64 IIIC 4	+	IL-2 NED PD PD 8.8 56.8 PD
LAU	1402 F 59 IIIA 4	+	IL-2 NED NED NED 49.1 49.1 Patient's	choice	
LAU	1504 M 37 IV 12 NED NED NED 20.2 20.2
all	patients 3/6 59	(36-67) 6	(1-12) 8.7 49.1
All	groups
3	-	IIIA 16	-	NED 8	-	NED 13-NED
3	-	IIIB 3	-	ED
5	-	IIIC 0	-	PD 11	-	PD 6-PD
8	-	IV
NED:	no	evidence	of	disease
ED:	evidence	of	disease
PD:	progressive	disease
*	The	patient	was	rendered	tumor-free	by	resection	of	a	left	axillary	metastase,	after	V6	
Discontinuation	
reason
Tumor	outcome Disease	Free	
Survival	
(months)
Overal	
Survival	
(months)
all	patients 5/146 59	(31-67) 8	(2-18)
Vaccines	
received
9.4 41.3
AJCC:	American	Joint	Committee	on	Cancer
Study	vaccination	
groups	 Patient	ID Sex	(F/M)
Age	at	study	
entry
AJCC	tumor	
staging	at	
study	entry
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Table II: Summary of frequencies of NY-ESO-1/DR7-specific CD4 T-cells, detected 870	
after 1 round of IVS in HLA-DR7+ patients 871	
 872	
 873	
LAU 331 19.60 ND ND 6.50 1.38 6.74
LAU 1293 2.94 2.52 5.00 ND ND ND
LAU 1352 1.72 ND 1.54 ND 4.91 8.62
LAU 1350 0.13 0.26 ND 6.80 ND ND
LAU 1357 0.18 0.55 ND 1.41 1.44 ND
LAU 1397 0.08 9.67 9.94 ND 3.35 ND
LAU 466 0.10 3.69 ND ND ND ND
Patient ID 12vacc.Before 2vacc. 4vacc. 6vacc. 8vacc.
ND: not done 
1. vaccination cycle (C1) 2. vaccination cycle (C2) 
3. vaccination cycle (C3) 
V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12 
PBMC PBMC PBMC PBMC PBMC 
IL-2 IL-2 IL-2 IL-2 IL-2 IL-2 IL-2 IL-2 IL-2 IL-2 IL-2 Group B 
(IL-2) 
Day:       -7     0         29 32 39          57          85 88 95          141    169    197    225 235          281   309  337   365 375 
Figure 1 Baumgaertner P., et al. 
Figure 2 Baumgaertner P., et al. 
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Supplemental Table I: HLA-typing of the patients.  Baumgaertner P., et al. 
Group&A&(no&IL,2)
LAU$986 A*0201&A30(19);&B49(21)&Bx;&C*04&C*07;&DRB1*0101,&*1102;&DPB1*0401,&*1401,&DRw52neg
LAU$205 A*0201&A3;&B*3501/27&B51;&DRB1*0101,&*13;&DPB1*0401,&*0402/0602;&DRw52neg
LAU$331 A*0201&A29(19);&B8&B44(12);&C*07&C*1601;&DRB1*0301,&*0701;&&DPB1*0101,&*1101;&DRw52pos
LAU$518 A23(9)&A31(19);&B39(16)&B44(12);&C*05&C*07;&DRB1*0401,&*0404;&DPB1*0401,&*0601;&DRw52neg
LAU$1280 A*03&A*29;&B*07&B*44;&C*07&C*1601;&DRB1*0801,&*1501;&DPB1*0401,&*2001;&DRw52neg
LAU$1330 A1&A26(10);&B44(12)&B35;&C*04&C*07;&DRB1*0401,&*12;&DPB1*0201,&*0401;&DRw52neg
LAU$1293 A3&A26(10);&B13&B56(22);&C*01&C*06;&DRB1*0701,&*0801;&DPB1*0301,&*0401;&DRw52neg
LAU$1286 A1&A*0201;&B8&B63(15);&C*07&C@;&DRB1*1102,&*1302;&DPB1*0201,&*1301;&DRw52pos
LAU$1352 A*0201&A3;&B35&B51;&C*04&C*16;&DRB1*0701,&*0801;&DPB1*0401,&*0402;&DRw52neg
LAU$1350 A*0205&A3;&B14&B15;&C*08&C*12;&DRB1*0701,&@&;&DPB1*0401,&@;&DRw52neg
Group&B&(IL,2)
LAU$1357 A*01&A*01;&B*07&B*44;&C*05&C*07;&DRB1*0701,&*1501;&DPB1*0401,&*1601
LAU$1397 A*0201&A1;&B13&B57;&DR&*0701,&*0701;&DQ&*0202,&*03;&DP&*0401,&*1701/&DRb&neg;&DR1&*07*01
LAU$1408 A*01&A*24;&B*14&B*44;&DR&*0102,&*0701;&DQ&*0202,&*05;&DP&*1101,&*1701
LAU$1415 A*01&A*33;&B*08&B*58;&DR&*03,&*13;&DQ&*0201,&*0609;&DP&*0501,&*2401;&DR52&*0101,&*0301;&DRw52&pos
LAU$1417 A*01&A*24;&B*35&B*51;&DR&*0101,&*1104;&DQ&*03,&*05;&DP&*0402,&*1001/&;&DRw52&neg
LAU$466 A2&A26;&B44(12)&B35or75?;&DR*0701,&*1104;&DQ*0202,&*03;&DP&*0401,&*1101/&DRw52&neg
LAU$1394 A3&A68;&B18&B51;&DR*1104,&*13;&DQ&*03,&*06;&DP&*0402,&*1001;&DR52&*0101,&*0202/&DRw52&neg
LAU$1402 A*26&A*33;&B*27&B*35;&DR&*04,&*1303;&DQ&*03,&*03;&DP&*0201,&*0401;&DRw52&neg
LAU$1504 A*01&A*11;&B*35&B*51;&DR&*04,&*11;&DQ&*03,&*03;&DP&*0301,&*0402
Patient$ID HLA$typingStudy$vaccination$groups
Supplemental Table II: Number of vaccination cycles completed and 
vaccines administered.  
Baumgaertner P., et al. 
Patients(
completed(
Cycle(1
Patients(
completed(
Cycle(2
Patients(
completed(
Cycle(3
Patients(
received(
Boost
Total(vaccines(
administered
Max(number(
vaccines(received(
per(patient
All#groups 16/19 .12/14 6/8 1 153 18
Group#A 9/10 8/9 4/6 1 97 18
Group#B 7/9 4/5 2/2 0 56 12
CTCAE:	Common	Terminology	Criteria	for	Adverse	Events	(AEs),	(Version	2.0,	April	30,	1999)	
SOC:	System	Organ	Class.		
The	MedDRA	terminology	was	developed	as	a	medically	validated	medical	terminology	for	uJlizaJon	throughout	the	regulatory	process.	A	SOC	is	the	highest	level	of	the	hierarchy	of	MedDRA	dicJonary		and	
disJnguished	by	anatomical	or	physiological	system,	eJology,	or	purpose.	CTCAE	terms	are	grouped	by	MedDRA	Primary	SOCs.	Within	each	SOC,	AEs	are	listed	and	accompanied	by	descripJons	of	severity	(Grade).	
	
CTCAE	severity	(grade)	scale:	1=mild,	2=moderate,	3=severe	and	4=life	threatening	
	SOC	 n	of	events n	of	patients %	of	patients n	of	events n	of	patients %	of	patients nof	events n	of	patients %	of	patients n	of	events n	of	patients %	of	patients
CARDIAC	DISORDERS 1 1 5 1 1 5 0 0 0 0 0 0
EAR	AND	LABYRINTH	DISORDERS 1 1 5 0 0 0 0 0 0 0 0 0
EYE	DISORDERS 5 2 11 0 0 0 0 0 0 0 0 0
GASTROINTESTINAL	DISORDERS 35 12 63 5 2 11 1 1 5 0 0 0
GENERAL	DISORDERS	AND	ADMINISTRATION	SITE	CONDITIONS 577 19 100 30 10 53 1 1 5 0 0 0
INFECTIONS	AND	INFESTATIONS 1 1 5 0 0 0 0 0 0 0 0 0
INVESTIGATIONS 3 2 11 0 0 0 0 0 0 0 0 0
METABOLISM	AND	NUTRITION	DISORDERS 2 1 5 0 0 0 0 0 0 0 0 0
MUSCULOSKELETAL	AND	CONNECTIVE	TISSUE	DISORDERS 79 11 58 15 7 37 0 0 0 0 0 0
NEOPLASMS	BENIGN,	MALIGNANT	AND	UNSPECIFIED	(INCL	CYSTS	AND	POLYPS) 1 1 5 0 0 0 0 0 0 0 0 0
NERVOUS	SYSTEM	DISORDERS 55 10 53 10 5 26 0 0 0 0 0 0
PSYCHIATRIC	DISORDERS 3 3 16 0 0 0 0 0 0 0 0 0
RESPIRATORY,	THORACIC	AND	MEDIASTINAL	DISORDERS 4 1 5 1 1 5 0 0 0 0 0 0
SKIN	AND	SUBCUTANEOUS	TISSUE	DISORDERS 9 5 26 2 2 11 0 0 0 0 0 0
VASCULAR	DISORDERS 5 4 21 0 0 0 0 0 0 0 0 0
Total	AEs 781 64 2 0
CTCAE	grade	1	adverse	events CTCAE	grade	2	adverse	events CTCAE	grade	3	adverse	events CTCAE	grade	4	adverse	events
Supplemental Table III: Toxicity profile, list of adverse events that 
were definitely, probably and possibly related to the study treatment, 
according to their CTCAE severity scale.  
 
Baumgaertner P., et al. 
Supplemental Table IV: Number of IL-2 injections administered and cumulative 
IL-2 dose received by patients in group B. 
 
Baumgaertner P., et al. 
LAU$1357 12 15$x$0.5$Mio$UI/m
2$$+$
6$x$0.25$Mio$UI/m2
18$Mio$UI
LAU$1397 8 70$x$0.5$Mio$UI/m2 70$Mio$UI
LAU$1408 1 ND 0
LAU$1415 5 36$x$0.5$Mio$UI/m2$$ 36$Mio$UI
LAU$1417 8 70$x$1$Mio$UI/m
2$$+$
27x$1.7$Mio$UI/m2
131.9$Mio$UI
LAU$466 2 10$x$1$Mio$UI/m2 16.7$Mio$UI
LAU$1394 4 30$x$1$Mio$UI/m2 63$Mio$UI
LAU$1402 4 25$x$1.5$Mio$UI/m2 75$Mio$UI
LAU$1504 12 ND 0
ND:$not$done
Study$
group Patient$ID
Vaccines$
received ILC2$injections
Group&B
Total$cumulative$
ILC2$doses
Supplemental Figure 1 Baumgaertner P., et al. 
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Supplemental Figure 1: IVS for the detection of antigen-specific CD4 and CD8 T-cells. CD8 T-cells were purified by positive 
selection using MACS isolation microbeads (Miltenyi) according to manufacturer’s recommendations, followed by CD4 T-cell 
positive selection starting from the CD8 negative fraction, using the same method. Positive T-cells were cultured in IVS and CD4/
CD8 depleted PBMCs were irradiated (30 Gy) and used as feeders for stimulation of the cultures. T-cells (either CD4 or CD8) 
and autologous APCs were mixed at 1:1 ratio and co-cultured for 14 days with 3 18-mers (NY-ESO-179-96, NY-ESO-185-102, NY-
ESO-191-108) spanning the entire vaccine NY-ESO-179-108 sequence, with 12 amino acids overlaps at 2 µM, in medium consisting 
of RPMI 1640 supplemented with 8% hear inactivated, pooled human serum. At day 2, 100 U/ml IL-2 was added and cultures 
were continued until day 14. Each individual initial culture was splitted separately when necessary. T-cell responses were 
evaluated after IVS in a 6-hour re-challenge experiment using overlapping peptide pools (2 µM final concentration) in the 
presence of Brefeldin A (10 µg/ml): for evaluation of CD4 T-cell responses 10 13-mer peptides overlapping by 11 amino acids 
were used, while for CD8 T-cell responses 22 9-mer peptides were pulsed on autologous PHA CD4 T-cell blasts for 1 hour, 
before addition to the CD8 T-cells. As negative control, each well was left unchallenged. As positive control, 2 wells for CD4 and 
CD8 T-cells were stimulated with PMA/Ionomycin in the presence of Brefeldin A and NY-ESO-1 restimulated T-cells were stained 
intracellularly for cytokines and analyzed by flow cytometry. 
 
Supplemental Figure 2 Baumgaertner P., et al. 
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Supplemental Figure 2:  Specific CD8 T-cell responses before and after vaccination with NY-ESO-1 LSP, 
in Groups A and B. A. Details of longitudinal NY-ESO-1-specific CD8 T-cell responses (IFNγ, TNFα, and 
IL-2) measured individually in each patient in Group A (left panels) and B (right panels), before and during 
vaccination. B. Polyfunctionality of NY-ESO-1-specific CD8 T-cell responses assessed as IFNγ+TNFα+ or 
IFNγ+TNFα+IL-2+ cells, measured individually in each patient in Group A (left panels) and B (right panels), 
before and during vaccination. C. Quantification of the contribution of each individual cytokine (IFNγ, TNFα 
and IL-2) to the NY-ESO-1-specific CD8 T-cell response, before and during vaccination. The mean of the 
response for each cytokine is shown for patients in Group A (upper pies) and B (lower pies). 
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Supplemental Figure 3: Specific CD4 T-cell responses before and after vaccination with NY-ESO-1 LSP, in 
Groups A and B. A. Details of longitudinal NY-ESO-1-specific CD4 T-cell responses (IFNγ, TNFα, IL2 and 
IL-13) measured individually in each patient in Group A (left panels) and B (right panels), before and during 
vaccination. B. Polyfunctionality of NY-ESO-1 specific CD4 T-cell responses assessed as IFNγ+TNFα+, or 
IFNγ+TNFα+IL-2+, or IFNγ+TNFα+IL-2+IL-13+ cells, measured individually in each patient in Group A (left 
panel) and B (right panel), before and during vaccination. C. Quantification of the contribution of each 
individual cytokine (IFNγ, TNFα, IL-13 and IL-2) to the NY-ESO-1-specific CD4 T-cell responses, before and 
during vaccination. The mean of the response for each cytokine is shown for patients in Group A (upper pies) 
and B (lower pies). 
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Supplemental Figure 4: Tumor antigen specific humoral responses. A. Plasma from patients before and 
during immunization was analyzed by ELISA for reactivity against recombinant NY-ESO-1, LAGE-1, Melan-
A, and MAGE-A10 proteins. Reciprocal titers were determined as described in Materials and methods part. 
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Supplemental Figure 5: Mapping and avidity evaluation of NY-ESO-1-specific CD8 T-cell responses in individual 
patients. A. Using individual 9-mer overlapping peptides covering the entire NY-ESO-1 LSP sequence, NY-
ESO-1-specific CD8 T-cell responses were mapped in 5 patients, by monitoring IFNγ+ TNFα+ CD8 T-cells after 6-
hour peptide challenge. B. Using serial dilutions of the pool of 9-mer overlapping peptides covering the entire NY-
ESO-1 LSP sequence, avidity of peptide recognition of NY-ESO-1-specific CD8 T-cell responses was assessed 
using ELISPOT assay for 6 patients. 
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Supplemental Figure 6: Gating strategy for identification of cytokine secreting T cells. The same strategy has 
been applied for both CD8 (shown heere) and CD4 T cells. 
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